In vitro antimicrobial susceptibility testing. Clinical implications and limitations.
D000617:Aminoglycosides / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use; D002701:Chloramphenicol / Q000627:therapeutic use; D004917:Erythromycin / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D006801:Humans; D006863:Hydrogen-Ion Concentration; D005779:Immunodiffusion; D007201:Indicator Dilution Techniques; D008034:Lincomycin / Q000627:therapeutic use; D008709:Methenamine / Q000627:therapeutic use; D008722:Methods; D008826:Microbial Sensitivity Tests / Q000592:standards*; D009268:Nalidixic Acid / Q000627:therapeutic use; D009582:Nitrofurantoin / Q000627:therapeutic use; D010403:Penicillin Resistance; D010406:Penicillins / Q000627:therapeutic use; D011113:Polymyxins / Q000627:therapeutic use; D013696:Temperature; D013752:Tetracycline / Q000627:therapeutic use
D000617:Aminoglycosides; D002511:Cephalosporins; D010406:Penicillins; D011113:Polymyxins; D009268:Nalidixic Acid; D004917:Erythromycin; D002701:Chloramphenicol; D009582:Nitrofurantoin; D008034:Lincomycin; D013752:Tetracycline; D008709:Methenamine